{"id":349149,"date":"2026-11-17T09:33:16","date_gmt":"2026-11-17T04:03:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=349149"},"modified":"2026-11-17T09:33:16","modified_gmt":"2026-11-17T04:03:16","slug":"gaudium-ivf-and-women-health-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/","title":{"rendered":"Gaudium IVF and Women Health Share Price Target 2027: 24.7% Upside to Rs 129, Bull Rs 155"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Gaudium IVF and Women Health share price Rs 103.42 (17 November 2026). Base target Rs 129, bull Rs 155, downside risk Rs 86.1. PE 33.82. 52W range Rs 69.18 to Rs 163.18.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Gaudium IVF and Women Health share price target<\/strong> for 2027 is <strong>Rs 129<\/strong>, about <strong>24.7%<\/strong> above the current price of Rs 103.42. The <strong>bull case<\/strong> is <strong>Rs 155<\/strong>, and the <strong>downside risk level<\/strong>, which is not a target, is <strong>Rs 86.1<\/strong>. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 20.5%, with the stock holding its PE of 33.82. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a <strong>Gaudium IVF and Women Health target price<\/strong> for 2027 should start with where the stock sits today. At Rs 103.42 on 17 November 2026, it is 36.6% below its 52-week high of Rs 163.18 and 49.5% above its 52-week low of Rs 69.18. That range spans 136% from low to high, so the entry point matters as much as the <strong>Gaudium IVF and Women Health price forecast<\/strong> itself.<\/p>\n<p>This article builds the <strong>Gaudium IVF and Women Health share price target<\/strong> from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the <strong>bull case<\/strong> and the <strong>downside risk level<\/strong> were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=gaudium-ivf-and-women-health-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Gaudium_IVF_and_Women_Health_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Gaudium IVF and Women Health Stock Analysis: Company Overview and Key Stats\">Gaudium IVF and Women Health Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Why_Is_Gaudium_IVF_and_Women_Health_Share_Price_Target_Set_at_Rs_129_for_2027\" title=\"Why Is Gaudium IVF and Women Health Share Price Target Set at Rs 129 for 2027?\">Why Is Gaudium IVF and Women Health Share Price Target Set at Rs 129 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Earnings_Growth_Behind_the_Gaudium_IVF_and_Women_Health_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Gaudium IVF and Women Health Target Price: Five Years of Results\">Earnings Growth Behind the Gaudium IVF and Women Health Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Valuation_Check_for_the_Gaudium_IVF_and_Women_Health_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Gaudium IVF and Women Health Stock Target: PE, Price to Book and ROE\">Valuation Check for the Gaudium IVF and Women Health Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Gaudium_IVF_and_Women_Health_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Gaudium IVF and Women Health Share Price Targets for the Short Term and 12 Months\">Gaudium IVF and Women Health Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Short_Term_Gaudium_IVF_and_Women_Health_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Gaudium IVF and Women Health Stock Target Levels: Technical Setup\">Short Term Gaudium IVF and Women Health Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#12_Month_Gaudium_IVF_and_Women_Health_Target_Price_for_2027\" title=\"12 Month Gaudium IVF and Women Health Target Price for 2027\">12 Month Gaudium IVF and Women Health Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Gaudium_IVF_and_Women_Health_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Gaudium IVF and Women Health Target Price\">How EPS Growth and PE Multiple Change the Gaudium IVF and Women Health Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Gaudium_IVF_and_Women_Health_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Gaudium IVF and Women Health Stock Target in 2027\">Bull Case and Downside Risk for Gaudium IVF and Women Health Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Bull_Case_Rs_155\" title=\"Bull Case Rs 155\">Bull Case Rs 155<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Downside_Risk_Level_Rs_861\" title=\"Downside Risk Level Rs 86.1\">Downside Risk Level Rs 86.1<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Key_Risks_to_the_Gaudium_IVF_and_Women_Health_Target_Price_for_2027\" title=\"Key Risks to the Gaudium IVF and Women Health Target Price for 2027\">Key Risks to the Gaudium IVF and Women Health Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Gaudium_IVF_and_Women_Health_Price_Target\" title=\"Growth Slowdown Risk for the Gaudium IVF and Women Health Price Target\">Growth Slowdown Risk for the Gaudium IVF and Women Health Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#How_to_Invest_in_Gaudium_IVF_and_Women_Health\" title=\"How to Invest in Gaudium IVF and Women Health\">How to Invest in Gaudium IVF and Women Health<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#FAQs_on_Gaudium_IVF_and_Women_Health_Share_Price_Target_2027\" title=\"FAQs on Gaudium IVF and Women Health Share Price Target 2027\">FAQs on Gaudium IVF and Women Health Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#What_is_the_Gaudium_IVF_and_Women_Health_share_price_target_for_2027\" title=\"What is the Gaudium IVF and Women Health share price target for 2027?\">What is the Gaudium IVF and Women Health share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#What_is_the_Gaudium_IVF_and_Women_Health_share_price_today\" title=\"What is the Gaudium IVF and Women Health share price today?\">What is the Gaudium IVF and Women Health share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Is_Gaudium_IVF_and_Women_Health_a_buy_or_sell_at_the_current_price\" title=\"Is Gaudium IVF and Women Health a buy or sell at the current price?\">Is Gaudium IVF and Women Health a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Gaudium_IVF_and_Women_Health_shares\" title=\"What are the bull case target and downside risk level for Gaudium IVF and Women Health shares?\">What are the bull case target and downside risk level for Gaudium IVF and Women Health shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#What_are_the_main_risks_to_the_Gaudium_IVF_and_Women_Health_price_target\" title=\"What are the main risks to the Gaudium IVF and Women Health price target?\">What are the main risks to the Gaudium IVF and Women Health price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#What_is_the_PE_ratio_of_Gaudium_IVF_and_Women_Health_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Gaudium IVF and Women Health and how does it compare with the industry?\">What is the PE ratio of Gaudium IVF and Women Health and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#Who_owns_Gaudium_IVF_and_Women_Health_and_what_is_the_promoter_holding\" title=\"Who owns Gaudium IVF and Women Health, and what is the promoter holding?\">Who owns Gaudium IVF and Women Health, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/gaudium-ivf-and-women-health-share-price-target-2027\/#What_were_Gaudium_IVF_and_Women_Healths_latest_quarterly_results\" title=\"What were Gaudium IVF and Women Health&#8217;s latest quarterly results?\">What were Gaudium IVF and Women Health&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Gaudium_IVF_and_Women_Health_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Gaudium IVF and Women Health Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gaudium IVF and Women Health (NSE: GAUDIUMIVF) has a market capitalisation of Rs 783.00 crore. In FY26 it reported revenue of Rs 104.89 crore and net profit of Rs 24.49 crore. The table collects the figures the <strong>Gaudium IVF and Women Health share price target<\/strong> is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/gaudiumivf\/gaudium-ivf-n-women-h-l-share-price-today\">Gaudium IVF and Women Health<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>GAUDIUMIVF<\/td>\n<\/tr>\n<tr>\n<td>CMP (17 November 2026)<\/td>\n<td>Rs 103.42<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 163.18<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 69.18<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 783.00 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>33.82<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>62.11<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>5.14<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>16.06%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.16<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 3.18<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.00%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 129<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 155<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 86.1<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Gaudium_IVF_and_Women_Health_Share_Price_Target_Set_at_Rs_129_for_2027\"><\/span><strong>Why Is Gaudium IVF and Women Health Share Price Target Set at Rs 129 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 3.18 grown for one year gives a forward <strong>EPS estimate<\/strong> of Rs 3.82, and multiplying it by the unchanged PE of 33.82 gives the <strong>Rs 129<\/strong> base-case <strong>Gaudium IVF and Women Health stock target<\/strong>. The <strong>bull case<\/strong> adds faster earnings growth and a higher multiple, while the <strong>downside risk level<\/strong> assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Gaudium_IVF_and_Women_Health_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Gaudium IVF and Women Health Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gaudium IVF and Women Health grew revenue from Rs 36.52 crore in FY22 to Rs 104.89 crore in FY26, a compound annual growth rate of 30.2%. Net profit grew more slowly, from Rs 8.83 crore to Rs 24.49 crore (29.0% a year), which points to margin pressure alongside the sales growth.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>36.52<\/td>\n<td>8.83<\/td>\n<td>1.44<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>44.26<\/td>\n<td>13.52<\/td>\n<td>2.20<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>53.75<\/td>\n<td>16.60<\/td>\n<td>2.70<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>70.96<\/td>\n<td>19.18<\/td>\n<td>3.12<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>104.89<\/td>\n<td>24.49<\/td>\n<td>3.92<\/td>\n<td>0.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 47.8%, faster than the four-year average of 30.2%, and net profit moved up 27.7%. EPS rose from Rs 2.70 in FY24 to Rs 3.92 in FY26. The <strong>FY27 outlook<\/strong> for the <strong>Gaudium IVF and Women Health price target<\/strong> depends on whether that <strong>EPS estimate<\/strong> keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gaudium IVF and Women Health converted 23.3% of FY26 revenue into net profit, against 27.0% in FY25, within a five-year range of 23.3% to 30.9%. EBITDA margin was 36.5% in FY26 versus 40.7% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 38.50 crore, up 20.8% from the same quarter a year earlier, while net profit of Rs 9.41 crore was up 0.3%. EBITDA came in at Rs 14.56 crore, up 4.7% year on year. The next quarterly result is the first test of whether the earnings assumption behind the <strong>Gaudium IVF and Women Health stock target<\/strong> holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.16, and shareholders&#8217; equity grew from Rs 9.29 crore in FY22 to Rs 152.30 crore in FY26. Operating cash flow in FY26 was Rs 7.25 crore against capital expenditure of Rs 6.72 crore, leaving free cash flow of Rs 0.53 crore, or 0.1% of the current market capitalisation. In FY25 free cash flow was negative at Rs 0.16 crore, so cash generation has not been steady year to year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Gaudium_IVF_and_Women_Health_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Gaudium IVF and Women Health Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 33.82 against an industry PE of 62.11, Gaudium IVF and Women Health trades at a discount to its industry. Price to book is 5.14 on a book value of Rs 20.92 per share, and return on equity is 16.06%. A PE of 33.82 equals an earnings yield of 3.0%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.00%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 71.29% of Gaudium IVF and Women Health in September 2026, and promoter holding fell from 99.98% in September 2025 to 71.29% in September 2026. Foreign institutional investors (FII) held 1.19% and domestic institutions (DII) held 2.22%, which puts total <strong>institutional holding<\/strong> at 3.41%. FII holding rose from 0.00% in September 2025 to 1.19% in September 2026. Public shareholders own the remaining 25.29%. Institutional holding this low means the stock sees limited professional coverage, and price moves can be sharper when trading volumes are thin.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Gaudium_IVF_and_Women_Health_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Gaudium IVF and Women Health Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Gaudium_IVF_and_Women_Health_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Gaudium IVF and Women Health Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 103.42 on 17 November 2026, Gaudium IVF and Women Health trades below its 50-day simple moving average of Rs 108.05 and below its 200-day exponential moving average of Rs 106.60. The 14-day RSI reads 56.1, which is neutral territory, and the MACD line sits above its signal line. The nearest <strong>resistance level<\/strong> is Rs 106.60 (200-day exponential moving average) and the nearest support is Rs 69.18 (52-week low). A sustained move above Rs 106.60 would improve the short-term setup, while a close below Rs 69.18 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Gaudium_IVF_and_Women_Health_Target_Price_for_2027\"><\/span><strong>12 Month Gaudium IVF and Women Health Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>12-month target<\/strong> of <strong>Rs 129<\/strong> means a move of 24.7% up from Rs 103.42 over the next 12 months. It would still leave the stock 20.9% below its 52-week high of Rs 163.18. Anyone checking the <strong>Gaudium IVF and Women Health share price target<\/strong> against their own view should focus on two inputs: the EPS estimate and the <strong>PE multiple<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Gaudium_IVF_and_Women_Health_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Gaudium IVF and Women Health Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 27.06<\/th>\n<th>PE 33.82<\/th>\n<th>PE 38.89<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 3.18)<\/td>\n<td>Rs 86.1<\/td>\n<td>Rs 108<\/td>\n<td>Rs 124<\/td>\n<\/tr>\n<tr>\n<td>20.0% (EPS Rs 3.82)<\/td>\n<td>Rs 103<\/td>\n<td>Rs 129<\/td>\n<td>Rs 149<\/td>\n<\/tr>\n<tr>\n<td>25.0% (EPS Rs 3.98)<\/td>\n<td>Rs 108<\/td>\n<td>Rs 135<\/td>\n<td>Rs 155<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the <strong>Gaudium IVF and Women Health price forecast<\/strong>, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Gaudium_IVF_and_Women_Health_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Gaudium IVF and Women Health Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_155\"><\/span><strong>Bull Case Rs 155<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case<\/strong> <strong>Gaudium IVF and Women Health price target<\/strong> needs EPS growth of 25.0%, which lifts forward EPS to Rs 3.98, and a <strong>PE multiple<\/strong> that rises 15% to 38.89. That gives <strong>Rs 155<\/strong>, 49.9% above the current price and below the 52-week high of Rs 163.18.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_861\"><\/span><strong>Downside Risk Level Rs 86.1<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 3.18 and the PE falls 20% to 27.06. That gives <strong>Rs 86.1<\/strong>, 16.7% below the current price and above the 52-week low of Rs 69.18.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>25.0%<\/td>\n<td>38.89<\/td>\n<td>Rs 155<\/td>\n<td>+49.9%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>20.0%<\/td>\n<td>33.82<\/td>\n<td>Rs 129<\/td>\n<td>+24.7%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>27.06<\/td>\n<td>Rs 86.1<\/td>\n<td>-16.7%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Gaudium_IVF_and_Women_Health_Target_Price_for_2027\"><\/span><strong>Key Risks to the Gaudium IVF and Women Health Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Gaudium_IVF_and_Women_Health_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Gaudium IVF and Women Health Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 20.8% year on year, and FY26 revenue growth was 47.8%. If growth slows from here, the EPS estimate behind the Gaudium IVF and Women Health stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gaudium IVF and Women Health has a market capitalisation of Rs 783.00 crore. <strong>Institutional holding<\/strong> is 3.41%, and promoters hold 71.29%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 23.3% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 33.82 versus an industry PE of 62.11, a de-rating toward the downside-risk PE of 27.06 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 56.1 and the MACD sits above its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time. Treat every <strong>Gaudium IVF and Women Health share price target<\/strong> as a range of outcomes rather than a single point.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Gaudium_IVF_and_Women_Health\"><\/span><strong>How to Invest in Gaudium IVF and Women Health<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any <strong>Gaudium IVF and Women Health share price target<\/strong> is only as current as the data behind it, and the data here is as of 17 November 2026, so refresh the Rs 103.42 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Gaudium IVF and Women Health&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Gaudium IVF and Women Health fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three <strong>Gaudium IVF and Women Health target price<\/strong> scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and <strong>resistance level<\/strong>s above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Gaudium IVF and Women Health live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Gaudium IVF and Women Health share price target<\/strong> for 2027 is Rs 129 in the base case, with <strong>Rs 155<\/strong> as the bull case. The support for that view is arithmetic you can check: EPS grew 20.5% a year over FY24 to FY26, and the stock trades at a PE of 33.82. The risks are equally concrete, including <strong>institutional holding<\/strong> of only 3.41% and a downside scenario that cuts the price 17% if earnings stall. Use these numbers as a framework for judging the <strong>Gaudium IVF and Women Health price target<\/strong>, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Gaudium_IVF_and_Women_Health_Share_Price_Target_2027\"><\/span><strong>FAQs on Gaudium IVF and Women Health Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Gaudium_IVF_and_Women_Health_share_price_target_for_2027\"><\/span><strong>What is the Gaudium IVF and Women Health share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Gaudium IVF and Women Health share price target for 2027 is Rs 129, which is 24.7% above the price of Rs 103.42 on 17 November 2026. The bull case is Rs 155 and the downside risk level, which is not a target, is Rs 86.1. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Gaudium_IVF_and_Women_Health_share_price_today\"><\/span><strong>What is the Gaudium IVF and Women Health share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 17 November 2026, before market open, Gaudium IVF and Women Health (NSE: GAUDIUMIVF) is quoted at Rs 103.42, which is its last closing price from the previous session. That is 36.6% below the 52-week high of Rs 163.18 and 49.5% above the 52-week low of Rs 69.18. The market capitalisation of Rs 783.00 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Gaudium_IVF_and_Women_Health_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Gaudium IVF and Women Health a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 20.5% a year over FY24 to FY26 and the base case implies 24.7% upside; on the cautious side, institutional holding is only 3.41%, and the downside risk level of Rs 86.1 is 17% below the current price. Whether Gaudium IVF and Women Health fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Gaudium_IVF_and_Women_Health_shares\"><\/span><strong>What are the bull case target and downside risk level for Gaudium IVF and Women Health shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Gaudium IVF and Women Health share price target for 2027 is Rs 155, which assumes 25.0% EPS growth and a PE of 38.89, a 15% re-rating from today&#8217;s multiple. That is 49.9% above the current price and below the 52-week high of Rs 163.18. The downside risk level is Rs 86.1, which assumes flat EPS and a PE of 27.06, 20% lower than today. It sits 16.7% below the current price and above the 52-week low of Rs 69.18, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Gaudium_IVF_and_Women_Health_price_target\"><\/span><strong>What are the main risks to the Gaudium IVF and Women Health price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Gaudium IVF and Women Health share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 783.00 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 27.06 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Gaudium_IVF_and_Women_Health_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Gaudium IVF and Women Health and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Gaudium IVF and Women Health is 33.82, against an industry PE of 62.11, which is a discount to the industry. Price to book is 5.14 and return on equity is 16.06%, and the PE equals an earnings yield of 3.0%. The base case holds the PE unchanged, so the Gaudium IVF and Women Health share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Gaudium_IVF_and_Women_Health_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Gaudium IVF and Women Health, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 71.29% of Gaudium IVF and Women Health in September 2026. FII held 1.19%, DII held 2.22% and the public held 25.29%. Together the two institutional groups hold 3.41%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Gaudium_IVF_and_Women_Healths_latest_quarterly_results\"><\/span><strong>What were Gaudium IVF and Women Health&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Gaudium IVF and Women Health reported revenue of Rs 38.50 crore (up 20.8% year on year) and net profit of Rs 9.41 crore (up 0.3%). For comparison, FY26 full-year revenue growth was 47.8% and net profit moved up 27.7%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Gaudium IVF and Women Health share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Gaudium IVF and Women Health share price target for 2027 is Rs 129, which is 24.7% above the price of Rs 103.42 on 17 November 2026. The bull case is Rs 155 and the downside risk level, which is not a target, is Rs 86.1. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Gaudium IVF and Women Health share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 17 November 2026, before market open, Gaudium IVF and Women Health (NSE: GAUDIUMIVF) is quoted at Rs 103.42, which is its last closing price from the previous session. That is 36.6% below the 52-week high of Rs 163.18 and 49.5% above the 52-week low of Rs 69.18. The market capitalisation of Rs 783.00 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Gaudium IVF and Women Health a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 20.5% a year over FY24 to FY26 and the base case implies 24.7% upside; on the cautious side, institutional holding is only 3.41%, and the downside risk level of Rs 86.1 is 17% below the current price. Whether Gaudium IVF and Women Health fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Gaudium IVF and Women Health shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Gaudium IVF and Women Health share price target for 2027 is Rs 155, which assumes 25.0% EPS growth and a PE of 38.89, a 15% re-rating from today's multiple. That is 49.9% above the current price and below the 52-week high of Rs 163.18. The downside risk level is Rs 86.1, which assumes flat EPS and a PE of 27.06, 20% lower than today. It sits 16.7% below the current price and above the 52-week low of Rs 69.18, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Gaudium IVF and Women Health price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Gaudium IVF and Women Health share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 783.00 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 27.06 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Gaudium IVF and Women Health and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Gaudium IVF and Women Health is 33.82, against an industry PE of 62.11, which is a discount to the industry. Price to book is 5.14 and return on equity is 16.06%, and the PE equals an earnings yield of 3.0%. The base case holds the PE unchanged, so the Gaudium IVF and Women Health share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Gaudium IVF and Women Health, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 71.29% of Gaudium IVF and Women Health in September 2026. FII held 1.19%, DII held 2.22% and the public held 25.29%. Together the two institutional groups hold 3.41%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Gaudium IVF and Women Health's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Gaudium IVF and Women Health reported revenue of Rs 38.50 crore (up 20.8% year on year) and net profit of Rs 9.41 crore (up 0.3%). For comparison, FY26 full-year revenue growth was 47.8% and net profit moved up 27.7%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gaudium IVF and Women Health share price target 2027: base Rs 129, bull Rs 155, downside risk level Rs 86.1, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":35,"featured_media":349148,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-349149","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["349148"],"rank_math_title":["Gaudium IVF and Women Health Share Price Target 2027: Bull Case"],"rank_math_description":["The Gaudium IVF and Women Health share price target for 2027 is Rs 129 against a price of Rs 103.42. See the bull case, downside risk and key risks. November 2026."],"rank_math_focus_keyword":["Gaudium IVF and Women Health share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/gaudium-ivf-and-women-health-share-price-target-2027-24-7-upside-to-rs-129-bull.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=349149"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349149\/revisions"}],"predecessor-version":[{"id":349150,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349149\/revisions\/349150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/349148"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=349149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=349149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=349149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}